JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN
Journal of Clinical Oncology (JCO) Podcast
Release Date: 10/27/2025
The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. John Gore and host Dr. Davide Soldato discuss JCO article, "," which compares radical cystectomy and bladder sparing therapy for patients with recurrent high-grade non-muscle invasive bladder cancer. Dr. Gore and Dr. Soldato focus on the study's patient-centered approach, eligibility criteria, and quality of life after treatment. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your host, Dr. Davide...
info_outline
Atezolizumab, Bevacizumab, and Non-Platinum Chemotherapy for PROC
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, “” by Harter et al. TRANSCRIPT Melis Canturk: Hello, and welcome to the . I'm your host, Melis Canturk, and today we will be discussing the article, “.” While integrating immune checkpoint inhibitors has revolutionized the treatment of various gynecologic cancers, these agents have historically shown limited single agent activity in ovarian cancer. Despite a strong biological rationale for combining immunotherapy with chemotherapy and bevacizumab to enhance T-cell infiltration and normalized...
info_outline
Ribociclib Plus Letrozole in Recurrent LGSOC: GOG 3026
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "" by Slomovitz et al. TRANSCRIPT Melis Canturk: Hello, and welcome to . I'm your host, Melis Canturk, and today we will be discussing the article, "." Building on the fact that more than 95% of low-grade serous carcinoma are estrogen receptor positive and often exhibit abnormalities in the CDK4/6 signaling pathway, researchers launched the GOG 3026 trial. This study investigated the effectiveness of pairing the CDK4/6 inhibitor ribociclib with letrozole, an aromatase inhibitor, adapting a...
info_outline
NCI Working Group on Biochemically Recurrent Prostate Cancer
Journal of Clinical Oncology (JCO) Podcast
Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population, the importance of PSA doubling time as a prognostic factor and with an emphasis on treatment de-escalation to limit toxicity and improve patient outcomes. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in...
info_outline
Association Between EOL SACT and Healthcare Utilization
Journal of Clinical Oncology (JCO) Podcast
Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article ",” highlighting adverse outcomes for patients who receive any type of systemic anticancer therapy(SACT) at EOL (end of life) and the need for better communication between oncologists and patients regarding expected risk and benefits of such treatments to properly align goals-of-care. TRANSCRIPT Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your host, , medical oncologist at Ospedale San Martino in...
info_outline
Milan Consensus Endpoints for Bladder Preservation in MIBC
Journal of Clinical Oncology (JCO) Podcast
Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article ",” focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to , the podcast where we sit down with authors from some of the latest articles published in the . I am your...
info_outline
JCO at 2025 ASH: Pirtobrutinib in Untreated CLL
Journal of Clinical Oncology (JCO) Podcast
JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I’m Jonathan Friedberg, editor of , and welcome to , where we are covering two manuscripts that were presented at the meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on...
info_outline
JCO at ASH 2025: A New Validated Staging System for AL Amyloidosis: AL-ISS
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Peter Li and author Dr. Jahanzaib Khwaja discuss the ASH 2025 Simultaneous Publication article, "." TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO’s Editorial Fellow, and today, I am joined by Dr. Jahanzaib Khwaja on . This is a simultaneous publication that will be presented at this year’s ASH Conference. At the time of this recording, our guest has disclosures that will be linked in the transcript. So, Dr. Khwaja, let’s...
info_outline
JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC
Journal of Clinical Oncology (JCO) Podcast
In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "" by Bradley, et al published October 13, 2025. TRANSCRIPT Dr. Ece Cali: Welcome to this episode of . This is Dr. Ece Cali, Editorial Fellow. Today I'm joined by Dr. Jeffrey Bradley, Professor of Radiation Oncology at the University of Pennsylvania, to discuss the manuscript, "" The PACIFIC-2 study was a phase III, double-blind, randomized trial comparing the efficacy and safety of simultaneous durvalumab with concurrent chemoradiation followed by consolidation...
info_outline
Health Outcomes in Older Childhood Cancer Survivors
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. Rusha Bhandari and host Dr. Davide Soldato discuss JCO article "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, " with a particular focus on mortality data, development of secondary malignancies and the importance of education for both patients and healthcare providers regarding long-term follow-up and care. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to , the podcast where we sit down with authors from some of the latest articles...
info_outlineIn this episode of JCO Article Insights, host Dr. Lauren Shih summarizes the article, "Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study" by Bourhis, et al published September 03, 2025
TRANSCRIPT